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Background: Decreasing salt consumption can prevent cardiovascular diseases (CVD). Practically, it is difficult to
promote people’s awareness of daily salt intake and to change their eating habits in terms of reducing salt intake
for better cardiovascular health. Health education programs visualizing daily dietary salt content and intake may
promote lifestyle changes in patients at high risk of cardiovascular diseases.
Methods/Design: This is a cluster randomized trial. A total of 800 high-CVD-risk patients attending diabetes and
hypertension clinics at health centers in Muang District, Chiang Rai province, Thailand, will be studied with
informed consent. A health center recruiting 100 participants is a cluster, the unit of randomization. Eight clusters
will be randomized into intervention and control arms and followed up for 1 year. Within the intervention clusters
the following will be undertaken: (1) salt content in the daily diet will be measured and shown to study
participants; (2) 24-hour salt intake will be estimated in overnight-collected urine and the results shown to the
participants; (3) a dietician will assist small group health education classes in cooking meals with less salt. The
primary outcome is blood pressure change at the 1-year follow-up. Secondary outcomes at the 1-year follow-up are
estimated 24-hoursalt intake, incidence of CVD events and CVD death. The intention-to-treat analysis will be
followed.
Blood pressure and estimated 24-hour salt intake will be compared between intervention and control groups at the
cluster and individual level at the 1-year follow-up. Clinical CVD events and deaths will be analyzed by time-event
analysis. Retinal blood vessel calibers of CVD-risk patients will be assessed cross-sectionally. Behavioral change to
reduce salt intake and the influencing factors will be determined by structured equation model (SEM). Multilevel
regression analyses will be applied. Finally, the cost effectiveness of the intervention will be analyzed.
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Discussion: This study is unique as it will recruit the individuals most vulnerable to CVD morbidity and mortality by
applying the general Framingham CVD risk scoring system. Dietary salt reduction will be applied as a prioritized,
community level intervention for the prevention of CVD in a developing country.
Trial registration: ISRCTN39416277
Keywords: Salt, CVD, Thailand, Behavior, InterventionBackground
Cardiovascular diseases (CVD) are the world’s largest
killers, causing more than 17 million estimated deaths
globally in 2008 [1]. Over 80% of these CVD deaths oc-
curred in low- and middle-income countries [1]. There
is an urgent need to prevent CVD morbidity and mortal-
ity in developing countries [2]. In Thailand, CVD events
are currently in the top three leading causes of death [3]
and leading causes of admissions to provincial and
community-level hospitals [4]. Thus, prevention of CVD
events in high-risk individuals would be the most cost-
effective strategy for reducing the morbidity and mortal-
ity caused by CVD in low-middle-income countries such
as Thailand [5].
Salt reduction at the community level is the WHO-
suggested strategy for prevention of CVD in developing
countries [2,6-8]. In recent years, it has become a proven,
effective strategy in many countries such as Finland,
Japan and some developed countries [6,9-11]. In Asia,
strokes are common CVD events, with hypertension as
the most attributable risk factor for CVD; consequently,
salt intake is likely to be the most important risk behavior
to be controlled for CVD prevention [12]. However, evi-
dence for implementation of reducing salt intake in the
developing country setting is still scarce and inadequate,
especially in Southeast Asian countries [13]. The cost
effectiveness of the salt reduction strategy for CVD
prevention is also yet to be determined [14].
Human beings love the taste of salt, and the consump-
tion of salty foods has become a well-entrenched dietary
habit [15]. Many patients with CVD risks know that a
high level of salt intake is a risky behavior. However,
changing the behavior to a reduction in salt intake is not
easily done in practice. It is necessary to strengthen the
hearsay knowledge and relayed massage among the
high-risk persons so that a strong perception will de-
velop, leading to behavioral change [16]. “Seeing is be-
lieving” [17]. We hypothesized that visualizing the salt
content in daily food and the rough amount of individ-
ual daily salt intake in high-risk persons could lead to
behavioral change.
In this study, we will research intensive health educa-
tion interventions that use visualization tools to make
individuals aware of their daily salt consumption. The
participants will be informed of the salt content in avariety of daily foods as well as their 24-hour estimated
salt intake by urine sodium measurement. The health
promotion strategy aims to reduce salt intake to prevent
CVD. The implementation of the strategy will be cen-
tered at community health centers in Chiang Rai prov-
ince in northern Thailand. It is expected to bring about
behavioral changes leading to voluntary salt reduction
among high-risk patients, thereby averting thousands of
CVD events and deaths.
Methods/Design
Study objectives
The primary objective is to compare the effectiveness of
health education via visualization of salt content in food,
soup and urine, with routine health education by means
of measuring blood pressure changes in high-CVD-risk
patients at 1-year follow-up.
The secondary objectives are: to compare the effective-
ness of specially designed health education with routine
health education by means of monitoring estimated daily
salt intake using urine sodium measurement, CVD inci-
dence and retinal vessel caliber changes among diabetic
and hypertension patients with high CVD risk. We will
also compare the cost-effectiveness of health education
via visualization of salt content in food, soup and urine
with routine health education among diabetic and hyper-
tensive patients with high CVD risk.
Design
This is a cluster randomized controlled trial (CRT). The
rationale for choosing a CRT design is to prevent con-
tamination by sharing second-hand massage between
participants of intervention and control arms. Instead of
randomizing the individual patient, clusters of eligible
patients will be randomly allocated into the intervention
and control arms. There will be two arms of CRT: the
salt reduction intervention arm and control arm. The
units of randomization are health centers.
Study site: clusters and characteristics of the clusters
The study will be conducted in Muang district, Chiang
Rai, the northernmost province of Thailand. Every health
center within the study site district, which has a hyper-
tension and diabetes clinic, will be screened for eligibility
criteria. In order to prevent an empty cluster, any health
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the hypertension and diabetes clinic will not be included.
In this study, one health center will form one cluster.
Each cluster will have 100 participants, and there will be
four clusters in each study arm. The locations of ran-
domly allocated clusters are as shown in Figure 1. The
study has been carefully designed to minimize the coeffi-
cient of variation among the clusters.
Map of the study area
Study population
In this study, the study population will comprise high-
CVD-risk patients stratified by the Framingham general
CVD risk scoring system [18,19]. Only those patients who
have a CVD risk score higher than 15% will be included.
Eligibility criteria for individual patients to enroll in the
study
Selection of participants will be according to the follow-
ing inclusion and exclusion criteria.
Inclusion criteria
1. Diabetic patients with high CVD risk according to
the Framingham general CVD risk score (>15%)
2. Hypertensive patients with high CVD risk according
to the Framingham general CVD risk score (>15%)
3. Patients who are willing to participate in the studyFigure 1 Map showing study area and clusters.Exclusion criteria
1. Any female patients who are pregnant or trying to
become pregnant
2. Patients aged younger than 35 years
3. Patients with documented type I diabetes
4. Those on long-term steroid therapy (more than
2 weeks)
5. Those on long-term non-steroidal
anti-inflammatory drugs (NSAIDs) (i.e., every day
for at least 1 year)
6. Patients with cancer
7. Patients with known secondary hypertension such
as primary aldosteronism, Cushing’s syndrome or
pheochromocytoma
8. Patients with severe chronic pulmonary diseases
using home oxygen therapy
9. Patients with chronic renal disease
(creatinine ≧ 2.0 mg/dl)
10. Patients with congestive heart failure
11. Those with known previous diagnosis of CVDEthical approval
The study protocol was approved by the Juntendo Uni-
versity Ethics Committee, Japan (no. 2011036) on 1 July
2011 and Chiang Rai Regional Hospital Ethics Commit-
tee, Thailand (no. CR0027.102/research/207) on 17 No-
vember 2011. The study has been registered as a current
Table 1 Overview of data collection and measurements in
both CRT arms
Follow-up
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13








Blood pressure x x x x x x x x x x x x x







CVD event x x x
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ard Randomized Controlled Trial Number Register
ISRCTN39416277 was assigned on 3 January 2012 [20].
Participants will be well informed about the study
process in their respective group of the study and will be
free to decide to participate in the trial (Autonomy) [21].
There are no racial or ethnic criteria for inclusion in the
study (Equity). Participants in both the control and
intervention groups will receive routine health services
and also some trial-related screening service benefits
such as salt intake estimation, lipid profile, hemoglobin
A1c and body composition measurements (Table 1).
There will be no introduction of risk to the participants
(Beneficence).Enrollment
There are 31 health centers in Muang District. We will
apply the criterion that there must be a minimum of 200
patients attending the diabetes and hypertension clinics
in the health centers. (Figure 2)This selection criterion is
set in order to obtain a sufficient number of high-CVD-
risk patients with a high enough Framingham general
CVD risk score (>15%) within the study site clusters.Using the existing provincial databases for screening,
eight health centers meet this criterion.Randomization and application of eligibility criteria
A statistician, blinded to the recoded number of health
centers, will generate the random allocation sequence
using Stata software, version 11 (College Station, TX,
USA). Simple randomization will be used to allocate the
eight clusters into intervention and control groups.
(Figure 2)Concealment of allocation
The study objectives will be clearly explained to the
directors of the health centers, the cluster representa-
tives. Informed consent and agreement to enroll in the
study will be requested before random allocation into
either arm of the study. Up until the point of enroll-
ment, the researcher and cluster representative cannot
know the allocation of the clusters. Only after the
agreement to enroll, the enrollment and the random
allocation will the procedures, applicable to their par-
ticular study group, be explained to the cluster repre-
sentatives, and this will be done on different days.
At the allocated health center, participants will be
recruited by fulfilling the eligibility criteria for individual
enrollment. Written informed consent for trial participa-
tion will be requested of eligible participants. Likewise,
the study participants will not know into which arm of
the study they will be allocated until they have enrolled
in the study. The participants will receive a thorough ex-
planation of the procedures of the arm to which their
attending health center has been randomly allocated.
They will not be informed or will be unaware of the fact
that there is another group in the study, nor will they be
informed of the procedures of the other arm.
Each health center will enroll 100 participants. Chron-
ology of the recruitment is as follows: When the patients
come to the health center for their routine check-up,
they will be invited to participate in the trial. On the next
visit, the eligibility criteria will be checked, and informed
consent will be obtained from those who are eligible.
Then, the participants will receive a detailed explanation
of the procedures of their respective study arm.Blinding
The cluster representatives will know their allocated arm
after random allocation, and the study procedure of only
their allocated arm will be explained to them. Individual
participants will be given information pertaining to the
study group in their allocated cluster only after enrollment,
and thus blinded. The nature of the study does not allow
double blinding. However, the cluster randomized trial
Figure 2 Flow chart for enrollment and follow-up plan for CRT. *The eligibility criteria refer to the inclusion and exclusion criteria under the
heading of study population. +Clusters are shown in Figure 1.
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the study.
Intervention
The two major components of the education program
are the visualization tools and the special health educa-
tion classes organized by the dietician. We hypothesized
that after seeing both the amount of their daily dietary













to the health center
2 Dietary salt content
in daily food/ soup
Pocket Salt-meter
PAL-ES2 Atago, Tokyo
On the 1- and
6-month visitmight be inspired to reduce dietary salt intake. There-
fore, we will use visualization tools to inform the
patients of their estimated 24-hour salt intake (Table 2).
Visualizing salt content of food by digital hand-held
“pocket” salt meter
Participants will be requested to bring their usual food
(e.g., curries, soup and fried foods) to the health center.
We will use the digital hand-held pocket PAL-ES2 salt
meter (Atago Co., Ltd, Tokyo, Japan) to measure the salt
concentrations in the participants’ food (Figure 3). The
salt content will be shown in displayed units of g/100 ml
[22]. This intervention informs the patients about the
amount of salt in their food.
Revealing estimated daily salt intake
A KME-03 salinity checker (KOUNO ME Institute,
Kanagawaken, Japan) will be used to determine the esti-
mated daily salt intake [23]. During each monthly health
center visit, participants in the intervention group will
Figure 3 Digital hand-held salt meter for measuring food salt
content [22].
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from overnight collected urine. The monthly serial
measurement of individual participants will be reported
using an in-line graph documenting whether the salt in-
take is above or below 6 g /day.Table 3 Study outcome, outcome measurement and
assessment methods
Outcome Assessment Outcome measure
Primary Blood pressure Omron HEM-907 IntelliSense
professional digital blood
pressure monitor
Secondary Individual salt intake
estimate/24-hour
Overnight urine collection
and measurement of urine sodium
using the KME-03 (average of
3 successive days’ measurements)
Clinical CVD risk General Framingham score
10-year risk
CVD incidence Diagnosis of each CVD event
and CVD death
Surrogate outcome Retinal vessel caliberHealth education class
The small group education class will meet two times:
the first, 1 month after enrollment and the second,
3 months after enrollment. The participants will be
requested to bring their daily food to the health centers.
The salt content in the home-made food such as soups,
curries and sauces will be analyzed by a PAL-ES2 digital
hand-held salt meter. The salt content in the processed
food such as canned food, ready-to-eat food and instant
noodles will be explained referring to the nutritional
facts labels. The dangers related to a high-salt diet such
as potential cardiovascular death, will be explained.
There will be a taste test for participants to determine
the saltiness of the sample food so that they can be
made aware that individual tastes are subjectively differ-
ent. After that, the dietician will explain how to reduce
the daily dietary salt content based on the recommen-
dations published by the Thailand Ministry of PublicHealth. These recommendations aim to reduce daily
salt intake to less than 2,400 mg of sodium/day [24].
The group education by a dietician will take 2 hours.
The education will focus on continuously motivating
the participants by serial assessment results and pro-
viding assistance to reduce daily dietary salt intake.
The dietician will identify the traditional high-salt
foods such as fish sauce, processed pork, and other
products, giving advice for alternative ways of cooking
palatable food without high salt levels. Dietary sodium
fact sheets will be provided for the patients to keep at
home.
Control group
Participants in the control arm will receive both routine
health care services and health education programs. The
measurement and assessment tests will also be provided
to the participants in the control arm (Table 1). Partici-
pants in the control arm will receive routine health edu-
cation, which is a brief individual education session not
particularly focused on salt reduction. The differences
between the two arms are (1) hypothesis-driven health
educational interventions and (2) revealing of the results
of the serial assessment tests, such as KME −03, to the




Salt reduction is defined as decreasing individual salt
intake to less than 6 g/day, according to the Thailand
Ministry of Public Health.
2 Diabetes
Diabetes mellitus is defined as either one of the
following criteria: HbA1c concentration of more
than 6.5% or fasting blood glucose of more than
126 mg/dl at least twice or an on the spot blood
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simultaneously with 2-h post-prandial blood glucose
of more than 200 mg/dl or history of taking oral
hypoglycemic drugs [25,26].
3 Hypertension
Hypertension is defined as a systolic blood pressure
(SBP) of ≥ 140 mmHg or a diastolic blood pressure
(DBP) of ≥ 90 mmHg and higher in subjects who are
not taking antihypertensive medication or subjects
who are taking the medication for hypertension [27].
4 Cardiovascular diseases (CVD) events
Myocardial infarction, coronary insufficiency,
unstable angina, ischemic stroke, hemorrhagic stroke,
transient ischemic attack (TIA), peripheral artery
disease or heart failure will be counted as CVD
events in this study. Patients with a known diagnosis
of CVD will be screened and excluded.
5 CVD mortality
This is defined as any documented death caused by
CVD during the study period.Study outcome and outcome measurements
Primary outcome
Blood pressure measurements will be used as the pri-
mary outcome of the study. Blood pressure will be mea-
sured serially at baseline and on the 3-, 6- and 12-month
follow-up visits of the trial (Table 3). It will assess the
impact of salt reduction on cardiovascular health. The
HEM-907 IntelliSense professional digital blood pressure
monitor (Omron Healthcare Inc., Lake Forest, IL, USA)
will be used to measure blood pressure (Table 3).Table 4 Confounder measurements
Confounder Variables How to measure
Demographic
characteristics




Lifestyle Smoking, alcohol Questionnaire
Genetic factor Family history of
diabetes/hypertension
Questionnaire
Drugs Different medications for
diabetes and hypertension
Clinical recordSecondary outcome
Individual salt intake will be monitored to assess the be-
havioral changes related to salt intake. Overnight col-
lected urine will estimate the salt intake by a KME-03
intake salinity checker [28-30]. The mean value of 3 suc-
cessive days’ measurements will be recorded and assessed
as outcome measures at baseline and on the 3- and 12-
month visits. The CVD risk assessment, CVD events and
CVD-related deaths will be followed up (Table 3). The
Framingham general CVD risk score will be measured at
study entry and assessed again at the end of the study
period to assess whether salt reduction decreases the
CVD risk. CVD event diagnosis will be based on the phy-
sician’s decision by clinical and confirmatory tests for re-
spective CVD events at regional- or district-level
hospitals. CVD events will be counted whenever they are
newly diagnosed among study participants. Deaths
caused by CVD and confirmed by the hospital records
will be counted as CVD deaths. A masked committee
consisting of two physicians who do not know the parti-
cipant’s study arm will confirm the CVD events. Also ofnote, the retinal vessels caliber measurement will be used
as a surrogate outcome for a CVD risk assessment.Sample size
For a conventional randomized control trial, a total of
240 participants, randomizing 120 into each arm, will
have enough power (90%) to detect the minimal differ-
ence of systolic blood pressure 130 (±20) and 120 (±20)
mmHg, diastolic pressure 90 (±20) and 80 (±20) mmHg,
difference in 24-hour estimated salt intake 10 (±5) and 8
(±4) g/day and CVD event rate of 0.15% and 0.08% be-
tween the control and intervention group with a 95%
confidence interval [6,31]. The cluster randomized trial
design used in RESIP-CVD might result in loss of power
and reduced efficiency. In this cluster randomized trial,
the number of participants in each cluster will be the
same, and other variable factors such as geography, food
tradition, race and dietary habits are assumed not to be
different for delineating the intracluster coefficient. To
compensate the design effect, the inflation factor has
been calculated by the formula (Deff= 1 + (m–1)ρ) where
Deff is inflation factor for design effect, m is the size of
each cluster, which is 30 and ρ is the intracluster coeffi-
cient which is assumed to be 0.07. The sample required
for a cluster randomized trial was inflated to 720. With a
loss to follow-up of approximately 10%, we expect that
the sample size of 800 patients will yield sufficient power
to detect the desired minimal difference in primary and
secondary outcomes between the intervention and con-
trol group. All eight clusters of the RESIP-CVD study
will enroll 100 eligible participants.
We identified the confounders and planned to collect
the information for multivariate analysis adjustment.
(Table 4)Data collection and follow-up
Before starting data collection, we completed feasibility
surveys at the study site clusters. A pilot intervention
was tested at a non-eligible health center. The timeline
of the data collection and assessment will be formatted
as seen in Table 1.
Aung et al. Trials 2012, 13:158 Page 8 of 10
http://www.trialsjournal.com/content/13/1/158Baseline survey
In this CRT, we wanted to test the health intervention in
high-CVD-risk patients. A low incidence of CVD events
in low-CVD-risk patients may warrant a larger sample
size than that we calculated and a longer follow-up than
we can perform. Therefore, we will recruit only the
high-CVD-risk patients stratified by using the Framing-
ham general CVD risk scoring system (10-year risk).
Calculation of the Framingham score will require infor-
mation such as age, sex, smoking status, systolic blood
pressure, history of taking antihypertensive drugs, his-
tory of diabetes and body mass index (BMI).
After recruitment, the Framingham score of the eli-
gible patients will be assessed in a baseline survey
[19,20]. The risk score calculator in formula excel spread
sheet published by the Framingham Heart Study will be
distributed to the study site HCs [32]. HC staffs will be
trained to apply it for the CVD risk stratification.
Follow-up plan
The staffs of the health centers will be reinforced with
additional staff from the research project. The researchFigure 4 Path model to analyze predictors of behavioral change by steam will call patients who failed to visit the health cen-
ter for the assessment. The research nurse in charge will
visit the patient’s house and collect the urine sample if
the participants are unable to come to the health center
on the appointed date for assessment. The control arm
participants will not have measurements as frequently as
the intervention group participants. At the health center
level, nurses are the main persons to follow up the
patients and deliver the drugs. Patients are usually re-
ferred to the district hospital or regional hospital when-
ever there is poor control of their disease or they have
problems such as a poor control of BP or blood glucose
level or any symptoms suggestive of CVD. We will use
this routine health system process to strengthen the fol-
low-up.
Analysis plan
The intention-to-treat analysis will be followed. The
mean blood pressure and mean daily salt intake of
both the intervention and control arms will be com-
pared at the individual level at the 1-year follow-up
using Student’s t test or the non-parametric test basedtructural equation modeling (SEM).
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both the cluster and individual levels. The CVD inci-
dence rate will be compared by time-to-event analysis.
A structural equation modeling analysis will be used
to determine the behavioral change predictors. Infor-
mation such as the self-efficacy, stage of attitudinal
change, decisional balance, family support, health cen-
ter support, ready-made meals usage and cooking
utensils will be collected by questionnaires and ana-
lyzed by the SEM (Figure 4).
Differences in CVD events and deaths and the asso-
ciated costs between intervention and control groups
will be estimated for up to 10 years after the interven-
tion. Lifetime costs and health outcomes for our study
population (aged 35 years and above) will be estimated
using data both in and outside of Thailand. Outcomes of
the analysis will be: CVD events and deaths averted and
the cost over 10 years, incremental cost-effectiveness
ratio (ICER) per CVD death averted, lifetime costs and
quality-adjusted life years (QALYs) gained and ICER per
QALYs gained. The analysis will be performed using a
societal perspective. All the future costs and outcomes
will be discounted at a rate of 3% per annum. Sensitivity
analysis will be employed to check the robustness of the
results. Budget impact analysis will be applied. From a
government perspective, the direct medical cost of
CVDs will be estimated both with and without special
health education in Chiang Rai Province in the course of
the next 10 years in order to assess its impact on the
Universal Health Coverage Scheme budget.
Discussion
There have been many previous studies related to salt
reduction interventions [33]. This current study is
unique as the study population is exclusively composed
of high-CVD-risk patients stratified by applying the
universal Framingham general CVD risk scoring sys-
tem. Therefore, the intervention can be prioritized, fo-
cusing on the high-risk individuals most vulnerable to
CVD morbidity and mortality at the community level
within a developing setting. The intervention will not
merely be a case of counseling and providing informa-
tion, however. The intervention group will be able to
clearly see and understand the salt level content in
their daily food and their estimated daily salt intake
following urinary salt measurement. Furthermore, we
will use equipment which is affordable within develop-
ing settings to visualize the salt content in food and
the patient’s urine. The effectiveness of the salt reduc-
tion intervention will be assessed by multiple outcomes
(Table 3).
In many previous clinical studies, reduced salt intake has
been shown by means of urinary sodium measurement in
urine collected over a period of 24-hours [8,34]. In thecurrent study, overnight urine will be collected and
assessed for urinary sodium [23,35]. This is a more feasible
and practicable outcome measurement that overcomes the
possible bias caused by under-collection of urine. In
addition, we will assess the blood pressure changes com-
paratively between participants in the intervention and
control groups. The reported incidence of CVD events and
deaths will be compared to determine the clinical effective-
ness of the health promotion intervention.
Health system costs and reimbursement systems differ
between developing and developed countries. Thailand
is a middle-income country in Southeast Asia, with
100% insurance coverage for non-communicable dis-
ease-related services. It is estimated that by allocating
just US$ 0.06 per person for voluntary salt reduction,
310,000 deaths can be prevented over a 10-year period
[36,37]. WHO has recommended salt reduction in
addition to risk modification by advocating multiple-
drug treatments using, for example, anti-hypertensive,
oral hypoglycemic agents and lipid-lowering medica-
tions. It is necessary to determine whether the preven-
tion of CVD incidence by a salt reduction strategy is
cost-effective in terms of treatment and health service
costs compared to traditional drug treatment that has
little concern for lifestyle modification [38]. The cost-
effectiveness analysis of our study is expected to answer
these questions for developing countries.
We have designed the study to have minimal residual
confounding factors and selected practical and contem-
porary approaches that overcome hard-to-achieve life-
style modifications. Thus, we expect that implementing
a health promotion intervention trial in a practical set-
ting will yield comprehensive and applicable evidence
for global reduction of CVD deaths and prevention of
CVD events.Trial status
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